ERC/mesothelin is expressed in human gastric cancer tissues and cell lines

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 27-33

  Ito, Tomoaki ^a   Kajino, Kazunori ^b   Abe, Masaaki ^b   Sato, Koichi ^a   Maekawa, Hiroshi ^a   Sakurada, Mutsumi ^a   Orita, Hajime ^a   Wada, Ryo ^a   Kajiyama, Yoshiaki ^b   Hino, Okio ^b  

^a JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C ERC mesothelin; ERC mesothelin; Gastric cancer; Mesothelin; N ERC mesothelin

Indexed keywords

MESOTHELIN; PROTEIN ERC; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; SUPERNATANT; TISSUE CULTURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; GPI-LINKED PROTEINS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891919468     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2803     Document Type: Article

References (25)

1. Hino O, Kobayashi E, Nishizawa M, et al: Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol 121: 602-605, 1995.
2. Yamashita Y, Yokoyama M, Kobayashi E, Takai S and Hino O: Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun 275: 134-140, 2000.
3. Hino O: Multistep renal carcinogenesis in the Eker (Tsc 2 gene mutant) rat model. Curr Mol Med 4: 807-811, 2004.
4. Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93: 136-140, 1996.
5. Hassan R, Bera T and Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res 10: 3937-3942, 2004.
6. Hassan R, Remaley AT, Sampson ML, et al: Detection and quan titation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12: 447-453, 2006.
7. Shiomi K, Miyamoto H, Segawa T, et al: Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 97: 928-932, 2006.
8. Inami K, Kajino K, Abe M, et al: Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. Oncol Rep 20: 1375-1380, 2008.
9. Shiomi K, Hagiwara Y, Sonoue K, et al: Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/meso thelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res 14: 1431-1437, 2008.
10. Yen MJ, Hsu CY, Mao TL, et al: Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 12: 827-831, 2006.
11. Argani P, Iacobuzio-Donahue C, Ryu B, et al: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7: 3862-3868, 2001.
12. Atmaca A, Pauligk C, Steinmetz K, Altmannsberger HM, Jäger E and Al-Batran SE: Prognostic impact of phosphorylated mitogen-activated protein kinase expression in patients with metastatic gastric cancer. Oncology 80: 130-134, 2011.
13. Wang L, Niu Z, Zhang L, et al: Clinicopathological significance of mesothelin expression in invasive breast cancer. J Int Med Res 40: 909-916, 2012.
14. Kawamata F, Homma S, Kamachi H, et al: C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma. J Gastroenterol: Mar 20, 2013 (Epub ahead of print).
15. Alvarez H, Rojas PL, Yong KT, et al: Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adeno carcinoma progression model: translational implications for diagnosis and therapy. Nanomedicine 4: 295-301, 2008.
16. Scholler N, Fu N, Yang Y, et al: Soluble member(s) of the meso thelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 96: 11531-11536, 1999.
17. Baba K, Ishigami S, Arigami T, et al: Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105: 195-199, 2012.
18. Einama T, Homma S, Kamachi H, et al: Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer 107: 137-142, 2012.
19. Hino O and Maeda M: Diagnostic tumor marker of asbestos-related mesothelioma. Environ Health Prev Med 13: 71-74, 2008.
20. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
21. Ishikawa K, Segawa T, Hagiwara Y, Maeda M, Abe M and Hino O: Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers. Pathol Int 59: 161-166, 2009.
22. Onda M, Nagata S, Ho M, et al: Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 12: 4225-4231, 2006.
23. Saeki H, Hashizume A, Izumi H, et al: The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma. Oncol Lett 4: 637-641, 2012.
24. Sharon E, Zhang J, Hollevoet K, et al: Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers. Clin Chem Lab Med 50: 721-725, 2012.
25. Creaney J, Francis RJ, Dick IM, et al: Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 17: 1181-1189, 2011.